Soleno acquired by Neurocrine for $2.9B after VYKAT XR approval in PWS; no remaining independent investment thesis exists

Bull

Neurocrine's established rare disease commercial infrastructure and balance sheet can accelerate VYKAT XR patient penetration well beyond the 12.5% of U.S. addressable market reached in Soleno's first nine months of launch. Neurocrine may pursue ex-U.S. regulatory pathways for VYKAT XR under a new strategy, and the strong $190M 2025 revenue run rate provides a credible foundation for a blockbuster franchise within Neurocrine's portfolio. Durable randomized withdrawal data presented at ENDO 2026 strengthens the clinical narrative for label maintenance and potential label expansion.

Bear

Neurocrine's voluntary withdrawal of the EU MAA signals a strategic de-prioritization of ex-U.S. markets, capping VYKAT XR's addressable opportunity to the U.S. alone and removing a significant long-term revenue driver. The 12% adverse-event discontinuation rate and a prescriber base of only 630 physicians suggest persistent adoption friction that Neurocrine must overcome to meaningfully grow beyond the current patient base of roughly 859 active patients. Integration disruption from replacing the entire legacy commercial team could slow new patient start momentum during the critical early growth phase.